(Q37784514)

23 August 2017

title

A 40-year journey in search of selective antiviral chemotherapy (English)

1 reference

23 August 2017

A 40-Year Journey in Search of Selective Antiviral Chemotherapy* (English)

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

4 July 2024

1 reference

Erik De Clercq

1

0 references

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20809796

4 July 2024

publication date

1 January 2011

1 reference

full work available at URL

23 August 2017

http://arjournals.annualreviews.org/doi/abs/10.1146/annurev-pharmtox-010510-100228

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20809796

https://www.annualreviews.org/doi/pdf/10.1146/annurev-pharmtox-010510-100228

4 July 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Annual Review of Pharmacology and Toxicology

4 July 2024

published in

1 reference

23 August 2017

volume

51

1 reference

23 August 2017

page(s)

1-24

1 reference

Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection

23 August 2017

cites work

1 reference

21 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/NATURE04295

Current Concepts of Interferon and Interferon Induction

1

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Antiviral Activity of Polyacrylic and Polymethacrylic Acids

4 July 2024

3

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Antiviral activity of polyacrylic and polymethacrylic acids. II. Mode of action in vivo

4 July 2024

4

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Requirement of a Stable Secondary Structure for the Antiviral Activity of Polynucleotides

4 July 2024

5

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Increase in antiviral activity of polynucleotides by thermal activation.

4 July 2024

6

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Interferon Induction Increased through Chemical Modification of a Synthetic Polyribonucleotide

4 July 2024

7

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

The role of interferon in the protective effect of a synthetic double-stranded polyribonucleotide against intranasal vesicular stomatitis virus challenge in mice

4 July 2024

8

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Thermal activation of the antiviral activity of synthetic double-stranded polyribonucleotides

4 July 2024

9

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Antiviral activity of polyribocytidylic acid in cells primed with polyriboinosinic acid

4 July 2024

10

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Induction of Circulating Interferon by Synthetic Anionic Polymers of Known Composition

4 July 2024

11

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Interferon induction in man by a synthetic polyanion of defined composition

4 July 2024

12

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Virus interference. I. The interferon

4 July 2024

13

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Inducers of interferon and host resistance. I. Double-stranded RNA from extracts of Penicillium funiculosum

4 July 2024

14

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes

4 July 2024

15

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Inducers of interferon and host resistance. 3. Double-stranded RNA from reovirus type 3 virions (reo 3-RNA).

4 July 2024

16

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Inducers of interferon and host resistance, IV. Double-stranded replicative form RNA (MS2-Ff-RNA) from E. coli infected with MS2 coliphage

4 July 2024

17

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Inducers of interferon and host resistance, V. In vitro studies

4 July 2024

18

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Viral infection and host defense

4 July 2024

20

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Isolation and structure of a human fibroblast interferon gene

4 July 2024

21

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Expression of human fibroblast interferon gene in Escherichia coli

4 July 2024

22

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Secretory proteins induced in human fibroblasts under conditions used for the production of interferon beta

4 July 2024

23

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Interferon and its inducers--a never-ending story: "old" and "new" data in a new perspective

4 July 2024

25

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster

4 July 2024

27

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

(E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent

4 July 2024

28

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine in severe herpes zoster

4 July 2024

29

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Looking back in 2009 at the dawning of antiviral therapy now 50 years ago an historical perspective

4 July 2024

30

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

(E)-5-(2-bromovinyl)-2'-Deoxyuridine in the treatment of experimental herpes simplex keratitis

4 July 2024

31

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Efficacy of (E)-5-(2-bromovinyl)-2'-deoxyuridine in the topical treatment of herpes simplex keratitis

4 July 2024

32

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Efficacy of bromovinyldeoxyuridine in the treatment of herpes simplex virus and varicella-zoster virus eye infections

4 July 2024

33

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Experimental stroma herpes simplex keratitis. Influence of treatment with topical bromovinyldeoxyuridine and trifluridine

4 July 2024

34

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Oral and topical treatment of experimental herpes simplex iritis with bromovinyldeoxyuridine

4 July 2024

35

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Bromovinyldeoxyuridine treatment of herpetic keratitis clinically resistant to other antiviral agents

4 July 2024

36

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo[2,3-d]pyrimidine nucleoside analogues

4 July 2024

37

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base

4 July 2024

38

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain

4 July 2024

39

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides

4 July 2024

40

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Antiviral drug discovery: ten more compounds, and ten more stories (part B).

4 July 2024

41

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus

4 July 2024

42

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

9-(2-Hydroxyethoxymethyl)guanine activity against viruses of the herpes group

4 July 2024

43

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine

4 July 2024

44

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine)

4 July 2024

45

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Topical treatment of experimental herpes simplex keratouveitis with 2'-O-glycylacyclovir. A water-soluble ester of acyclovir

4 July 2024

46

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy

4 July 2024

48

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

6-Deoxyacyclovir: a xanthine oxidase-activated prodrug of acyclovir

4 July 2024

49

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Drug Metabolism and Disposition

4 July 2024

50

25

805

Rashidi MR

1997

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Antiviral, antimetabolic and antineoplastic activities of 2'- or 3'-amino or -azido-substituted deoxyribonucleosides

4 July 2024

51

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro

4 July 2024

52

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides

4 July 2024

53

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase

4 July 2024

54

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro.

4 July 2024

55

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Potent and selective in vitro activity of 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) against human immunodeficiency virus

4 July 2024

56

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Inhibitory effect of 2',3'-didehydro-2',3'-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus

4 July 2024

57

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Early nucleoside reverse transcriptase inhibitors for the treatment of HIV: a brief history of stavudine (D4T) and its comparison with other dideoxynucleosides

4 July 2024

58

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog

4 July 2024

59

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity

4 July 2024

60

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

4 July 2024

61

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.

4 July 2024

62

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

The history of antiretrovirals: key discoveries over the past 25 years

4 July 2024

63

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine.

4 July 2024

64

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents

4 July 2024

65

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Acyclic nucleoside phosphonates: a key class of antiviral drugs

4 July 2024

66

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

(S)-9-(2,3-Dihydroxypropyl)adenine: An Aliphatic Nucleoside Analog with Broad-Spectrum Antiviral Activity

4 July 2024

67

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

S-adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents

4 July 2024

69

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

The acyclic nucleoside phosphonates from inception to clinical use: historical perspective

4 July 2024

70

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

A novel selective broad-spectrum anti-DNA virus agent

4 July 2024

71

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines

4 July 2024

72

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections

4 July 2024

73

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Another ten stories in antiviral drug discovery (part C): "Old" and "new" antivirals, strategies, and perspectives

4 July 2024

74

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Yet another ten stories on antiviral drug discovery (part D): paradigms, paradoxes, and paraductions

4 July 2024

75

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art.

4 July 2024

78

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents

4 July 2024

79

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Synthesis and in vitro evaluation of a phosphonate prodrug: bis(pivaloyloxymethyl) 9-(2-phosphonylmethoxyethyl)adenine

4 July 2024

80

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Oral formulations of adefovir dipivoxil: in vitro dissolution and in vivo bioavailability in dogs.

4 July 2024

81

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro

4 July 2024

82

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis

4 July 2024

83

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection

4 July 2024

84

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture

4 July 2024

85

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

4 July 2024

86

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

4 July 2024

87

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

4 July 2024

88

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

4 July 2024

89

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

9-[(2RS)-3-fluoro-2-phosphonylmethoxypropyl] derivatives of purines: a class of highly selective antiretroviral agents in vitro and in vivo

4 July 2024

90

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine

4 July 2024

91

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA

4 July 2024

92

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity

4 July 2024

95

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines

4 July 2024

96

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity

4 July 2024

97

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Deoxythreosyl phosphonate nucleosides as selective anti-HIV agents

4 July 2024

98

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds

4 July 2024

99

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity

4 July 2024

100

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Antivaccinia activities of acyclic nucleoside phosphonate derivatives in epithelial cells and organotypic cultures

4 July 2024

101

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Activities of acyclic nucleoside phosphonates against Orf virus in human and ovine cell monolayers and organotypic ovine raft cultures

4 July 2024

102

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models

4 July 2024

103

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Pronounced in vitro and in vivo antiretroviral activity of 5-substituted 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy] pyrimidines

4 July 2024

104

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Novel acyclic nucleoside phosphonate analogues with potent anti-hepatitis B virus activities

4 July 2024

105

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Intracellular metabolism of the new antiviral compound 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine

4 July 2024

106

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue

4 July 2024

107

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Intracellular metabolism of the nucleotide prodrug GS-9131, a potent anti-human immunodeficiency virus agent

4 July 2024

108

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131.

4 July 2024

109

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation.

4 July 2024

110

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

N6-cyclopropyl-PMEDAP: a novel derivative of 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) with distinct metabolic, antiproliferative, and differentiation-inducing properties

4 July 2024

111

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma

4 July 2024

113

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase

4 July 2024

114

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development

4 July 2024

115

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

What can be Expected from Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) in the Treatment of Human Immunodeficiency Virus Type 1 (HIV-1) Infections?

4 July 2024

116

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.

4 July 2024

117

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future

4 July 2024

118

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative

4 July 2024

119

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine

4 July 2024

120

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives

4 July 2024

121

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives

4 July 2024

122

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase

4 July 2024

123

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

4 July 2024

Molecular Pharmacology

124

39

805

Baba M

1991

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro

4 July 2024

125

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1.

4 July 2024

126

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds

4 July 2024

127

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later

4 July 2024

128

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase

4 July 2024

129

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU).

4 July 2024

130

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues

4 July 2024

131

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues

4 July 2024

132

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

4 July 2024

133

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).

4 July 2024

134

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.

4 July 2024

135

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Antiviral Drug Strategies

4 July 2024

136

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

4 July 2024

137

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate

4 July 2024

138

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

The survival benefits of AIDS treatment in the United States

4 July 2024

139

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

4 July 2024

Entecavir surprise

140

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

A preemptive strike against HIV.

4 July 2024

141

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine

4 July 2024

142

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2).

4 July 2024

143

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection

4 July 2024

144

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

4 July 2024

145

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

Antiviral agents active against influenza A viruses.

4 July 2024

146

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

The war against influenza: discovery and development of sialidase inhibitors

4 July 2024

147

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

The way forward in HCV treatment--finding the right path

4 July 2024

148

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

The design of drugs for HIV and HCV

4 July 2024

149

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

The bicyclam AMD3100 story

4 July 2024

150

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil).

4 July 2024

151

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-PHARMTOX-010510-100228

4 July 2024

Identifiers

1 reference

23 August 2017

1 reference